Withdrawn Drug Library

Catalog No. L1030

Withdrawn drugs refer to compounds that were once approved by regulatory agencies (such as tFDA, EMA, PMDA, etc.) but were later withdrawn from the market or forcibly delisted due to safety concerns (e.g., severe hepatotoxicity, cardiotoxicity, teratogenicity), insufficient efficacy, or commercial reasons.
Despite being removed from their original clinical indications, most of these molecules have completed comprehensive preclinical studies and at least Phase I–III clinical trials. They are characterized by well-defined target mechanisms, favorable bioavailability, and well-documented human pharmacokinetic and toxicological profiles. Their “failure” often reflects an unfavorable risk–benefit balance in specific patient populations or indications, rather than a lack of intrinsic biological activity.
A classic example is Thalidomide. In the 1960s, it was urgently withdrawn worldwide due to its severe teratogenicity. Shortly after its withdrawal, however, researchers gradually uncovered its unique immunomodulatory and anti-angiogenic activities. Under strict risk management programs, thalidomide was subsequently re-approved for the treatment of multiple myeloma and erythema nodosum leprosum, and further inspired the development of safer and more effective derivatives, including Lenalidomide and Pomalidomide.
TargetMol’s Withdrawn Drug Library comprises 264 globally withdrawn small-molecule drugs, spanning multiple therapeutic areas such as anti-infectives, cardiovascular diseases, neurological disorders, oncology, and metabolic diseases.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.